Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Details)

v3.19.1
Shareholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended
Oct. 25, 2018
Sep. 30, 2016
Mar. 31, 2019
Mar. 31, 2018
Jan. 25, 2019
Dec. 31, 2018
Dec. 21, 2018
Shareholders' Equity (Textual)              
Stock based compensation     $ 88,205 $ 1,023,496      
Common stock, shares issued     27,656,121     23,640,621  
Strategic Advisory Board Amendments [Member]              
Shareholders' Equity (Textual)              
Restricted common stock, description The SAB Amendments extend the term of the agreements from November 1, 2018 until October 31, 2019 and provide for the following equity-based compensation: (a) for Dr. Frost, an award of 150,000 shares of the Company's unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company's unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments).            
Stock Award Agreements [Member]              
Shareholders' Equity (Textual)              
Stock based compensation       $ 944,300      
Unamortized stock compensation     $ 31,667        
Expense     $ 72,500        
Description of equity based compensation     The SAB Amendments extend the term of the agreements from May 1, 2017 until April 30, 2018 and provide for the following equity based compensation: (a) for Dr. Frost, a warrant to purchase 2,000,000 shares of the Company's Common Stock (the "Frost Warrant") and an award of 150,000 shares of the Company's unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company's unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments). The Warrant has a term of five years and exercise price of $1.00 per share subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events. The Company recognized $39,791 expense for the pro rata portion of shares earned by the two members during the three months ended March 31, 2018, amortizing the expense over the 12 months of the service agreement regardless of the vesting condition.        
Stock Compensation Plan [Member]              
Shareholders' Equity (Textual)              
Aggregate shares of common stock   1,349,000          
Restricted common stock, description   The Company issued 1,349,000 shares of restricted common stock outside of the 2015 Equity Plan to Jay Nussbaum, Felicia Hess, Daniyel Erdberg, Kendall Carpenter, Mike Silverman and Reginald Brown pursuant to Stock Award Agreements. The shares will vest upon consummation of a significant equity and/or debt financing of at least $5,000,000 provided that the holder remains engaged by the Company through the vesting date. On August 3, 2017, these awards were modified so that the restrictions set forth in the RSA lapse upon the earlier of (i) consummation of a significant equity and/or debt financing from which the Company receives gross proceeds of at least $7,000,000 or (ii) a change in control (as defined in the RSA Amendment), provided that, in either case, the holder remains engaged by the Company through the date of such event.          
Shares vest upon consummation of equity and/or debt financing   $ 5,000,000          
Amended and Restated Stock Purchase Agreement [Member]              
Shareholders' Equity (Textual)              
Common stock, shares issued         4,015,500    
Common stock per price             $ 0.50
Cash and notes receivable             $ 2,007,750